Matching articles for "Abstral"
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1544 · April 9, 2018
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Topical Opioid Analgesics

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):e64-7
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Issue 1379 · December 12, 2011
Fentanyl Nasal Spray (Lazanda) for Pain

The FDA has approved a nasal spray formulation of fentanyl ( Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy.…

Med Lett Drugs Ther. 2011 Dec 12; 53(1379):99-100
The FDA has approved a nasal spray formulation of fentanyl ( Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.
Issue 1364 · May 16, 2011 Free
In Brief: Fentanyl Sublingual Tablets (Abstral) for Breakthrough Cancer Pain

The FDA has approved the marketing of fentanyl sublingual tablets ( Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid…

Med Lett Drugs Ther. 2011 May 16; 53(1364):40
The FDA has approved the marketing of fentanyl sublingual tablets ( Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. It is the fourth transmucosal formulation of fentanyl to become available in the US for this indication. 1-3 The manufacturer recommends an initial dose of 100 mcg, a maximum of 2 doses per breakthrough pain episode, and use for no more than 4 breakthrough pain episodes per day. As with all formulations of fentanyl, strong inhibitors of CYP3A4 such as clarithromycin ( Biaxin , and others) or itraconazole ( Sporanox , and others) can increase serum concentrations of the drug to levels that can cause respiratory depression even in opioid- tolerant patients. A single dose of any formulation of transmucosal fentanyl could be fatal for a child. 1. Fentanyl buccal tablet (Fentora) for breakthrough pain. Med Lett Drugs Ther 2007; 49:78. 2. Drugs for pain. Treat Guidel Med Lett 2010; 8:25. 3. Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain. Med Lett Drugs Ther 2010; 52:30. Download U.S. English